May 2026 in “RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218” This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.
December 2023 in “Research in pharmacy” This review underscores the importance of phytotherapeutic compounds and adjuncts in managing polycystic ovarian syndrome but does not present new clinical evidence.
48 citations
,
January 2000 in “Hormone Research in Paediatrics” This article reviews the regulation of androgens in human skin and adrenals, highlighting their role in skin disorders, but reports no new research findings.
September 2022 in “Women's healthcare” This review discusses various aspects of polycystic ovary syndrome, including its prevalence, diagnosis, and treatment options, and reports no new empirical results.
May 2026 in “International Journal of Current Pharmaceutical Review and Research” This article discusses the causes of polycystic ovary syndrome, including environmental pollutants, genetics, and oxidative stress, and explains how these factors contribute to symptoms like irregular menstrual cycles and obesity without reporting new clinical results.
